Press Releases + New Year: - Any -2024202320222021202020192018201720162015201420132012201120102009 Items per page 102550 Date Title and Summary View Toggle SummaryFeb 03, 2014 Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma View HTML Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma 18.3 KB Toggle SummaryJan 27, 2014 Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration View HTML Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration 20 KB Toggle SummaryJan 23, 2014 Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase View HTML Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase 14.6 KB Toggle SummaryJan 21, 2014 Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis View HTML Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis 69.4 KB Toggle SummaryJan 15, 2014 Galectin Therapeutics Supports Investigational New Drug (IND) Application for Its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma IND Submitted by Providence Portland Medical Center, a Leading Cancer Immunotherapy Research Institute View HTML Galectin Therapeutics Supports Investigational New Drug (IND) Application for Its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma 19.4 KB Toggle SummaryJan 13, 2014 Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis View HTML Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 19 KB Toggle SummaryJan 10, 2014 Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million View HTML Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million 14.1 KB Toggle SummaryJan 08, 2014 Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity View HTML Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity 16.8 KB Toggle SummaryJan 06, 2014 Galectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis View HTML Galectin Therapeutics Receives US Patent for Combination Treatment for Liver Fibrosis 67.9 KB Toggle SummaryDec 19, 2013 Published Preclinical Study Demonstrates Therapeutic Effect of Galectin Inhibitors in Fatty Liver Disease With Fibrosis View HTML Published Preclinical Study Demonstrates Therapeutic Effect of Galectin Inhibitors in Fatty Liver Disease With Fibrosis 18.7 KB Pagination First page First Previous page Previous … Page 24 Current page 25 Page 26 Page 27 … Next page Next Last page Last
Galectin Therapeutics and Providence Portland Medical Center Receive OK From FDA to Proceed With Phase 1B Clinical Trial in Metastatic Melanoma 18.3 KB
Galectin Therapeutics Inc. and SBH Sciences, Inc. Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration 20 KB
Galectin Therapeutics Executive Chairman James Czirr to Present at RedChip Emerging Growth Showcase 14.6 KB
Preclinical Study Demonstrates Effect of Galectin Inhibitor on Serum Biomarker in Fatty Liver Disease With Fibrosis 69.4 KB
Galectin Therapeutics Supports Investigational New Drug (IND) Application for Its Galectin Inhibitor GR-MD-02 in Metastatic Melanoma 19.4 KB
Galectin Therapeutics Announces Completion of Enrollment in First Cohort of Phase 1 Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis 19 KB
Galectin Therapeutics Reports on Key 2013 Scientific, Development and Regulatory Milestones, Highlights Corporate and Financial Activity 16.8 KB
Published Preclinical Study Demonstrates Therapeutic Effect of Galectin Inhibitors in Fatty Liver Disease With Fibrosis 18.7 KB
